# Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.

> **NCT05111626** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Amgen** · enrollment: 515 (actual)

## Conditions studied

- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Bemarituzumab
- **DRUG:** Nivolumab
- **DRUG:** Chemotherapy
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05111626
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-14
- **Primary completion:** 2025-10-14
- **Final completion:** 2027-01-29
- **Target enrollment:** 515 (ACTUAL)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05111626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05111626, "Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05111626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*